United States v. Moshe Milstein

481 F.3d 132, 2007 U.S. App. LEXIS 7034
CourtCourt of Appeals for the Second Circuit
DecidedMarch 26, 2007
DocketDocket 06-1869-CR
StatusPublished
Cited by13 cases

This text of 481 F.3d 132 (United States v. Moshe Milstein) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Moshe Milstein, 481 F.3d 132, 2007 U.S. App. LEXIS 7034 (2d Cir. 2007).

Opinion

RAKOFF, District Judge.

Defendant-Appellant Moshe Milstein appeals from a judgment of the United States District Court for the Eastern District of New York (Dearie, J.) entered April 14, 2006, which, following our remand in United States v. Milstein, 401 F.3d 53 (2d Cir.2005) (per curiam), re-sentenced Milstein to a term of imprisonment of 20 months and restitution in the amount of approximately $3.5 million. Familiarity with the facts and procedural background of this case, as set forth in our prior opinion in Milstein, are here assumed.

Milstein was convicted by a jury of fraudulently distributing misbranded drugs in interstate commerce, in violation of 21 U.S.C. §§ 331(a) and 333(a)(2) (Count Three); knowingly distributing wholesale prescription drugs in interstate commerce *134 without a required state license, in violation of 21 U.S.C. §§ 331(t), 333(b)(1), and 353(e)(2)(A) (Count Four); knowingly distributing prescription drugs in violation of criminal trademark laws, 18 U.S.C. § 2320(a) (Count Two); distributing wholesale prescription drugs without providing the required history of transactions, in violation of 21 U.S.C. §§ 331(t), 333(a)(2), and 353(e)(1)(A) (Count Five); and conspiracy to commit the offenses specified in Counts Two, Three, and Four, in violation of 18 U.S.C. § 371 (Count One). The gist of the Government’s case was that Milstein and others, taking advantage of the existence of less expensive (and less regulated) foreign versions of prescription drugs sold in the United States, purchased large quantities of three such drugs on the foreign market, repackaged them with counterfeit packaging so as to pass them off as their domestic counterparts, and sold them to doctors, pharmacists and pharmaceutical suppliers.

The original indictment, returned on September 16, 1998, alleged with respect to Count Three that Milstein and others had sold “re-packaged drugs as if they were the original product from the licensed manufacturers, thus distributing misbranded drugs.” See Milstein, 401 F.3d at 64. Some time after the original indictment was handed down, but before trial, tests performed by the Government and subsequently disclosed to the defense indicated that some of the repackaged drugs were contaminated with bacteria and endotoxins, even though they were labeled as “sterile.” Id. This evidence was put before the grand jury, but neither the superseding indictment returned on January 26, 2000 nor the second superseding indictment returned after the trial began amended Count Three to add further allegations regarding this contamination. Id. Nevertheless, the Government presented evidence of the contamination at trial and the district judge charged the jury that it could convict on the misbranding count either on a false origin theory or on a contamination theory. Id.

On appeal, we held that the contamination theory amounted to a constructive amendment that did not “place Milstein on notice that the Government would ... attempt to prove that the drugs were not sterile.” Id. at 65. In all other challenged respects, however, we affirmed the conviction. Id. at 75. Accordingly, we vacated the conviction on Count Three only, and remanded for a retrial on Count Three if the Government wished to re-try that count, and, in any event, for re-sentencing.

On remand, the Government chose not to re-try Count Three, and the District Court re-sentenced Milstein. Although the District Court was in no way bound by its prior sentence, it chose to sentence Milstein to the same terms and conditions as the previous sentence, except, importantly, for the prison term, which was 20 months instead of the prior 48 months.

Following entry of judgment, defendant returned to this Court claiming to raise two new issues on appeal: (i) whether our conclusion that Count Three, the substantive misbranding count, had been constructively amended also required us to vacate Count One, the conspiracy count, which charged, inter alia, a conspiracy to commit the misbranding offense set out in Count Three; and (ii) whether the District Court erred in ordering Milstein to make restitution of approximately $3.5 million to the two companies whose trademarks he had misappropriated. 1

*135 The first issue, however, is far from “new” for the very same argument was expressly rejected in our prior decision. See Milstein, 401 F.3d at 66 (“We reject ... Milstein’s contention that reversal of Count Three requires reversal of all counts .... [T]he contamination evidence was admissible in connection with Count One.... ”). As we there explained, the jury, as charged, was not presented with a constructive amendment of Count One and would have considered the contamination evidence, as far as the conspiracy count was concerned, as evidence of overt acts taken in furtherance of the conspiracy. Id. at 70-71. It is well settled that the “overt act element of a conspiracy charge may be satisfied by an overt act that is not specified in the indictment ... so long [as] there is no prejudice to the defendant.” United States v. Frank, 156 F.3d 332, 337 (2d Cir.1998) (per curiam); see also United States v. Armone, 363 F.2d 385, 400 (2d Cir.1966). Since the contamination evidence was disclosed to the defense five months before trial, there was no prejudice in its introduction for this purpose. See Milstein, 401 F.3d at 71. Milstein’s arguments to the contrary have gained no greater force in the 25 months since we previously rejected them.

The second issue, involving restitution, is, however, genuinely new, since it was not raised on the first appeal but was not thereby waived because Milstein was re-sentenced “de novo.” See United States v. Quintieri, 306 F.3d 1217, 1225 (2d Cir.2002) ce rt. denied, 539 U.S. 902, 123 S.Ct. 2246, 156 L.Ed.2d 110 (2003).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Rainford
110 F.4th 455 (Second Circuit, 2024)
Roundtree v. Reynolds
E.D. Wisconsin, 2024
United States v. Mustafa
Second Circuit, 2018
United States v. Anthony Cuti
708 F. App'x 21 (Second Circuit, 2017)
United States v. Charles Jones
616 F. App'x 726 (Fifth Circuit, 2015)
United States v. Wright
936 F. Supp. 2d 538 (E.D. Pennsylvania, 2013)
United States v. Gregory Fair
699 F.3d 508 (D.C. Circuit, 2012)
United States v. Johnson
790 F. Supp. 2d 945 (E.D. Wisconsin, 2011)
United States v. Bengis
631 F.3d 33 (Second Circuit, 2011)
United States v. Holland
394 F. App'x 766 (Second Circuit, 2010)
United States v. Wilfong
551 F.3d 1182 (Tenth Circuit, 2008)
United States v. Dove
585 F. Supp. 2d 865 (W.D. Virginia, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
481 F.3d 132, 2007 U.S. App. LEXIS 7034, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-moshe-milstein-ca2-2007.